Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JHP Pharmaceuticals Acquired by Warburg Pincus

Published: Friday, January 04, 2013
Last Updated: Thursday, January 03, 2013
Bookmark and Share
Warburg Pincus acquires JHP for $195 million on a debt- free, cash-free basis.

JHP Pharmaceuticals, LLC has announced that it has been acquired by an affiliate of Warburg Pincus from JHP Holdings, LLC, an entity majority-owned by Morgan Stanley Principal Investments, for $195 million on a debt- free, cash-free basis.

JHP’s current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.

Since its founding in 2007, JHP has developed into a leading specialty pharmaceutical company focused on the $30 billion U.S. sterile injectable drug market.

JHP’s established market presence, high-quality sterile manufacturing facility, and experienced management team, coupled with growth capital and support from Warburg Pincus, will enable the company to pursue unique partnership and acquisition opportunities in both the branded and generic segments of the sterile injectable market.

“Over the past five years, JHP has established itself as a strong injectable pharmaceutical business manufacturing and marketing its own branded and generic products, developing a strong generic products pipeline, and supporting other pharmaceutical companies in the development and manufacturing of innovative products,” said Stuart Hinchen, co-founder and CEO of JHP.

Hinchen continued, “In 2013, we will launch the first products from our strong pipeline of generic products. We believe Warburg Pincus is an ideal partner for JHP’s growth and expansion in the coming years. Warburg Pincus has deep experience in healthcare and pharmaceuticals in particular and is well known for its proven ability to strengthen the platforms of its portfolio companies.”

“With the support of Warburg Pincus, we will be able to embrace a more expansive strategy that will result in a considerably deeper and broader development pipeline for JHP,” said Peter Jenkins, co-founder of JHP.

“We have been impressed with the financial performance and quality record of JHP over the last five years, and are very pleased to contribute to the further development of the company,” said Elizabeth H. Weatherman, Managing Director and Head of the Healthcare Group, Warburg Pincus.

Weatherman continued, “The management team has done an excellent job building the company and we are delighted they are remaining with the business and co-investing. JHP represents an attractive investment opportunity for us and we have reserved a sizeable amount of additional capital to fund growth opportunities that will transform the business well beyond what it is today.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

JHP Pharmaceuticals Adds Second Product to Multi-Year Contract Manufacturing Agreement
Company will manufacture and supply an injectable anesthetic agent.
Friday, March 02, 2012
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Company has entered into an agreement to produce clinical trial batches of an innovative drug used in the treatment of heart failure.
Thursday, July 28, 2011
JHP Names Hinchen CEO
Stuart Hinchen will succeed Peter Jenkins as chief executive officer of JHP Pharmaceuticals.
Friday, July 01, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!